Nanopath has developed a platform for rapid, point-of-care biomarker purification and characterization from a patient sample. Our technology was originally developed at Dartmouth College as part of our PhD research, and is using advances in bioengineering and nanotechnology to reduce noise and improve signal in diagnostic systems. This allows for an integrated system that takes a complex patient sample, isolates key biomarkers, and analyses them without the need for lengthy clinical workflows. We believe that this new diagnostic paradigm has applications to a range of disease indications including bloodstream infections, cancer liquid biopsy, urinary tract infections, respiratory infections, and wound infections.
Fungal bioproduction makes up 50% of the industrial enzymes market, a $10B market with a CAGR of 7.1% yearly. Fungal production of enzymes requires that large, dense cultures of cells be aerated properly. Dense cultures, however, become very viscous; stirring these cultures to provide oxygen can damage cells. Aethergen introduces mutations into fungi which convey morphology beneficial for fermentation processes, and lower oxygen consumption by half. This alleviates the need for a tradeoff between culture density and oxygen transfer. Aethergen can thus offer both enzyme manufacturers and strain improvement companies a more efficient process, lowering raw material costs and increasing margins.
Cancer patients, after the first diagnosis often ask, “how bad is my tumor and what should I do if it is bad?” In about half of all cancer patients, the first line of chemotherapy fails, disease recurs, and patients die. Episteme has succeeded in targeting a specific epigenetic signature of pancreatic cancer patients, which could potentially be reverted by epigenetic drugs making the tumors amenable to chemotherapy. Episteme invented a novel microarray-based platform technology called “ATAC-Array”. This proprietary technology avoids the time and cost of next-generation ATAC library sequencing – the only microarray that reads chromatin accessibility. No other test provides such a comprehensive, cost-effective and clinically useful epigenetic summary. Episteme offers a personalized theragnostic test utilizing ATAC-array, histopathology and immunohistochemistry, to predict chemotherapy response and stratifying cancer patients to epigenetic (reprograming) therapy for better outcome and better quality of life.
Tuberculosis (TB) is the leading infectious disease cause of death worldwide, including in persons with HIV infection. Drug-resistant TB, an increasingly global epidemic, requires prolonged treatment with toxic, expensive drugs. BCG, the only vaccine currently in use for the prevention of TB, is very effective for the first few years of life but loses efficacy after 10-15 years. The only new vaccine to have shown efficacy in humans in a fully-powered Phase 3 trial is the booster vaccine being developed by investigators at Dartmouth College. DAR-901 is the most advanced and promising candidate in the global portfolio. Pre-clinical studies include a tuberculosis challenge study indicating DAR-901 is superior to the BCG booster vaccine.
Natural product molecules (and derivatives) are important for the development of modern drugs, as they play a vital role in the pipeline for new therapeutics. For example, >100 FDA-approved drugs are derived from tetracyclic terpenoids, which can be metabolized by the body into steroids. Despite this success, there remain considerable limitations to broad medicinal exploitation of the class due to lingering scientific challenges associated with compound availability. Carbacyclix has developed a concise asymmetric route to forging natural and unnatural (enantiomeric) C19 and C20 tetracyclic terpenoid skeletons suitable to drive medicinal exploration. While efforts have been focused on establishing the chemical science, early investigations reveal that the emerging chemical technology can deliver compositions of matter that are potent and selective agonists of the estrogen receptor beta.